BiologicalDrug
Tezepelumab clinical trials
Also written AMG 157, Tezspire and MEDI9929.
- studies test it
- 47
- open now
- 13
- in phase 3
- 21
- first study started
- 2008
Keep track of what changes. Save the tezepelumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
47 studies that test it; most in 2019 (7)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 14
- Phase 3
- 21
- Phase 4
- 2
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 23
Who runs them
Industry 33 · Other 14
AstraZeneca (24) · Amgen (5) · MedImmune LLC (3) · McMaster University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Imperial College London (1) · Dr. Anne Ellis (1) · University Hospital, Montpellier (1)
Studies
Open first, then newest update. How each study uses tezepelumab is read from its arms, and is right about nine times in ten.
Testing it · 47
- Efficacy of Tezepelumab in Peanut Oral ImmunotherapyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07015996Written as Tezepelumab
- A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With TezepelumabRecruitingPhase 3AstraZenecaNCT07520162Written as Tezepelumab
- A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaRecruitingPhase 3AstraZenecaNCT06023589Written as Tezepelumab
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)RecruitingPhase 3AstraZenecaNCT06878261Written as Tezepelumab
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)RecruitingPhase 3AstraZenecaNCT06883305Written as Tezepelumab
- Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabRecruitingPhase 3AstraZenecaNCT07363642Written as Tezepelumab
- Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation RecipientsRecruitingPhase 2Hopital FochNCT07771855Written as Tezepelumab
- Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary AspergillosisNot yet recruitingNot applicableQianfoshan HospitalNCT07757841Written as Tezepelumab
- Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)RecruitingPhase 4University of AlbertaNCT06705764Written as Tezepelumab
- Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe AsthmaNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07302516Written as tezepelumab (Arm1&Arm2)
- Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingNot applicableMedical University of ViennaNCT07046117Written as Tezepelumab
- Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe AsthmaNot yet recruitingPhase 3Dr. Andrew Thamboo, MDNCT06740045Written as Tezepelumab
- Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPDRecruitingPhase 2Asger SverrildNCT05507242Written as Tezepelumab
- A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With TezepelumabActive, not recruitingPhase 3AstraZenecaNCT06706817Written as Tezepelumab
- Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisActive, not recruitingPhase 3AstraZenecaNCT05583227Written as Tezepelumab
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United StatesCompletedPhase 4AstraZenecaNCT05329194Written as Tezepelumab
- REVErsing Airway Remodelling With TezepelumabCompletedPhase 3University Hospital, MontpellierNCT05651841Written as Tezepelumab
- Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent AsthmaTerminatedPhase 3AstraZenecaNCT05398263Written as Tezepelumab
- Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With PolyangiitisActive, not recruitingPhase 2Imperial College LondonNCT06230354Written as Tezepelumab
- Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal PolyposisCompletedPhase 3AstraZenecaNCT04851964Written as Experimental: Tezepelumab
See all 47 studies that test tezepelumab →
Given in every arm · 2 — tezepelumab is usual care beside what is tested
- Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With TezepelumabNot yet recruitingPhase 3University Hospital, MontpellierNCT07013123Written as Tezepelumab
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.Active, not recruitingPhase 3AstraZenecaNCT06473779Written as Tezepelumab
As the comparator · 2 — what is tested is compared with tezepelumab
- Physical Activity Promotion and Clinical Remission in Severe AsthmaRecruitingNot applicableUniversity of LeedsNCT07735494Written as Tezepelumab
- A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy SubjectsNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07327697Written as Tezspire
Codes
What other systems call tezepelumab · ClinicalTrials.gg INT000785
- MeSH (NLM) C000622721tezepelumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RJ1IW3B4QXTEZEPELUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2587789One source FDA
- Wikidata Q25326702tezepelumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152582TezepelumabOne source FDA
- DrugBank DB15090One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000622721 | tezepelumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RJ1IW3B4QX | TEZEPELUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2587789 | — | One source FDA |
| Wikidata | Q25326702 | tezepelumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152582 | Tezepelumab | One source FDA |
| DrugBank | DB15090 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.